In summary, these results suggest that the constitutive activation of KRAS‐TOPK axis contributes to the malignant progression of NSCLC, and targeting this axis could serve as a targeted therapy for NSCLC treatment. This evidence concerns the gene KRAS and non-small cell lung carcinoma.